A
A.T. van der Ploeg
Researcher at Erasmus University Rotterdam
Publications - 84
Citations - 4178
A.T. van der Ploeg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Enzyme replacement therapy & Glycogen storage disease type II. The author has an hindex of 31, co-authored 84 publications receiving 3884 citations. Previous affiliations of A.T. van der Ploeg include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Recombinant human acid α-glucosidase Major clinical benefits in infantile-onset Pompe disease
Priya S. Kishnani,Deyanira Corzo,Marc Nicolino,Barry J. Byrne,Hanna Mandel,Wuh-Liang Hwu,Nancy D. Leslie,J. Levine,Carolyn T. Spencer,Marie T. McDonald,Jennifer S. Li,J. Dumontier,M. Halberthal,Yin-Hsiu Chien,Robert J. Hopkin,S. Vijayaraghavan,Daniel Gruskin,D. Bartholomew,A.T. van der Ploeg,John P. Clancy,R. Parini,G. Morin,M Beck,G. S. De la Gastine,M. Jokic,Beth L. Thurberg,Susan M. Richards,Deeksha Bali,M. Davison,M. A. Worden,Yuan-Tsong Chen,James E. Wraith +31 more
TL;DR: Recombinant human acid α-glucosidase is safe and effective for treatment of infantile-onset Pompe disease and may have contributed to their improved response compared to previous trials with recombinant human acids in which patients were older.
Journal ArticleDOI
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients
M.L.C. Hagemans,Leon P. F. Winkel,P.A. van Doorn,W. J. C. Hop,M. C. B. Loonen,A. J. J. Reuser,A.T. van der Ploeg +6 more
TL;DR: It is concluded that early manifestations in childhood require proper attention to prevent unnecessary delay of the diagnosis and the follow-up of patients with late-onset Pompe's disease should focus on respiratory and limb-girdle muscle function, the capacity to perform daily activities, and the presentation of fatigue and pain.
Journal ArticleDOI
Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.
M.G.E.M. Ausems,J Verbiest,J Verbiest,Mmp Hermans,Mmp Hermans,Marian A. Kroos,Frits A. Beemer,Jhj Wokke,Lodewijk A. Sandkuijl,Lodewijk A. Sandkuijl,A.J.J. Reuser,A.T. van der Ploeg +11 more
TL;DR: The predicted frequency of Glycogen storage disease type II is about two to four times higher than previously suggested, which is a reason to become more familiar with the presentation of GSD II in its different clinical forms and to adjust the risk assessment for genetic counselling.
Journal ArticleDOI
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Lpf Winkel,Jmp van den Hout,Jhj Kamphoven,Jam Disseldorp,M Remmerswaal,W. F. M. Arts,Mcb Loonen,Arnold G. Vulto,P.A. van Doorn,G De Jong,Wim C. J. Hop,Gerrit Smit,SK Shapira,Marijke Boer,O. P. van Diggelen,A.J.J. Reuser,A.T. van der Ploeg +16 more
TL;DR: It is demonstrated that recombinant human α‐glucosidase from rabbit milk has a therapeutic effect in late‐onset Pompe's disease and there is good reason to continue the development of enzyme replacement therapy for Pompe's Disease.
Journal ArticleDOI
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
J. M. P. Van den Hout,A.J.J. Reuser,J. B. C. de Klerk,Willem F. M. Arts,Jan A.M. Smeitink,A.T. van der Ploeg +5 more
TL;DR: The positive preliminary results stimulate continuation and extension of efforts towards the realization of enzyme therapy for Pompe disease.